CapsoVision (NASDAQ:CV) Trading Down 6.5% - Here's Why

Shares of CapsoVision, Inc. (NASDAQ:CV - Get Free Report) were down 6.5% during trading on Friday . The company traded as low as $12.90 and last traded at $12.98. Approximately 11,088 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 163,197 shares. The stock had previously closed at $13.88.Wall Street Analysts Forecast GrowthHidden Gems: 3 Value Stocks to Watch for Strong 2025 ReturnsA number of research analysts recently commented on the company. Benchmark restated a "speculative buy" rating on shares of CapsoVision in a research note on Friday, November 14th. Zacks Research raised shares of CapsoVision to a "hold" rating in a report on Wednesday, November 5th. Weiss Ratings reissued a "sell (e)" rating on shares of CapsoVision in a research note on Monday. Finally, Roth Capital set a $7.00 price target on shares of CapsoVision in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CapsoVision presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.00.Get Our Latest Stock Report on CVCapsoVision Stock Performance2 Small-Cap Stocks Set to Shine in a Bull MarketThe firm's 50 day moving average is $7.18. CapsoVision (NASDAQ:CV - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The company had revenue of $3.54 million during the quarter. Institutional Investors Weigh In On CapsoVisionCavco's Future Looks Bright as Affordable Housing Demand SoarsAn institutional investor recently bought a new position in CapsoVision stock. New York State Common Retirement Fund bought a new position in shares of CapsoVision, Inc. (NASDAQ:CV - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,114 shares of the company's stock, valued at approximately $34,000. About CapsoVision (Get Free Report)CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out. In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.Read MoreFive stocks we like better than CapsoVisionWashington prepares for warDo you know what Amazon is planning for January 1?Turn your "dead money" into $306+ monthly (starting this month)$100 Trillion “AI Metal” Found in American Ghost TownWall Street Stockpicker Names #1 Stock of 2026This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CapsoVision Right Now?Before you consider CapsoVision, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CapsoVision wasn't on the list.While CapsoVision currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here